Phio Pharmaceuticals
PHIO
3 hedge funds and large institutions have $3.78M invested in Phio Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
51% more capital invested
Capital invested by funds: $2.5M → $3.78M (+$1.28M)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$2.69M |
| 2 |
Renaissance Technologies
New York
|
+$336K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.13M |
| 2 |
TAM
Tocqueville Asset Management
New York
|
-$90K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$30K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Broadfin Capital
New York
| $3M | +$2.69M | +8 | +400% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $268K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $248K | +$336K | +1 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $130K | – | – | – |
|
|
VKH
5
Virtu KCG Holdings
New York
| $49K | – | – | – |
|
|
CS
6
Credit Suisse
Zurich,
Switzerland
| $37K | – | – | – |
|
|
BW
7
Bison Wealth
Atlanta,
Georgia
| $13K | – | – | – |
|
8
Goldman Sachs
New York
| $13K | – | – | – |
|
|
PSUF
9
People's United Financial
Bridgeport,
Connecticut
| $7K | – | – | – |
|
10
Northern Trust
Chicago,
Illinois
| $6K | – | – | – |
|
11
Jane Street
New York
| $5K | – | – | – |
|
12
Bank of America
Charlotte,
North Carolina
| $3K | – | – | – |
|
13
Morgan Stanley
New York
| $1K | – | – | – |
|
|
AIG
14
American International Group
New York
| $557 | – | – | – |
|
|
TCM
15
Tang Capital Management
San Diego,
California
| – | -$1.13M | -3 | Closed |
|
|
BIM
16
BlackRock Investment Management
Wilmington,
Delaware
| – | -$2K | – | – |
|
|
17
Nomura Holdings
Tokyo,
Japan
| – | -$30K | – | – |
|
|
TAM
18
Tocqueville Asset Management
New York
| – | -$90K | – | – |
|
PHIO Hedge Fund Activity: Q2 2015 in Review
3 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2015, worth a combined $3.78M — up 51% from $2.5M a quarter earlier.
Fund positioning in PHIO was balanced in Q2 2015: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $2.69M. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.13M sold.
- 3 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $3.78M of Phio Pharmaceuticals stock for Q2 2015, up 51% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q2 2015 and 1 closed out, a net change of 0 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2015 was Broadfin Capital, an estimated $2.69M added.
- The largest Phio Pharmaceuticals seller in Q2 2015 was Tang Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2015.